|
Product Information |
|
Product name |
Molnupiravir / EIDD-2801 / MK448 |
|
CAS No. |
2349386-89-4 |
|
Molecular Formula |
C13H19N3O7 |
|
Molecular Weight |
329.31 |
|
Quality Standard |
98% up by HPLC |
|
Appearance |
White powder |
|
COA of Molnupiravir |
|
ITEMS |
SPECIFICATION |
RESULT |
|
Appearance |
White to off-white powder |
White powder |
|
Solubility |
Sparingly soluble in methanol ,practically insoluble in water |
Complies |
|
Identity |
IR Spectrum of the test is concordant with the IR spectrum of the standard, obtained in the samemanner. |
Complies |
|
Related Substance |
Any single impurity not more than 0.1% |
0.04% |
|
Total impurities are not more than1.0% |
0.1% |
|
|
Limit of residual solvents |
2-propanol ≤ 5000ppm |
75 ppm |
|
Ethanol ≤ 5000ppm |
162 ppm |
|
|
Ethyl acetate ≤ 5000ppm |
Not detected |
|
|
Cyclohexane ≤ 3880ppm |
1 ppm |
|
|
Loss on drying |
≤ 0.5% |
0.12% |
|
Residue on ignition |
≤ 0.1% |
0.03% |
|
Heavy metals |
≤ 0.02% |
Complies |
|
Assay |
98.0～102.0% |
99.5% |
|
Conclusion |
Complies with the specification |
|
|
Usage |
Function of Molnupiravir
Molnupiravir / EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad-spectrum antiviral activity against influenza virus and multiple coronaviruses (e.g., SARS-ChemicalbookCoV-2, MERS-CoV, SARS-CoV). EIDD-2801 has the potential to treat the novel coronavirus COVID-19 as well as seasonal and pandemic influenza.
sinoway a été créé en 1987, et est spécialisé dans la recherche, le développement, la fabrication sur mesure et le commerce d'apis pharmaceutiques, intermédiaires, santé et amp; compléments alimentaires, matières premières cosmétiques, extraits de plantes, fdfs et service personnalisé dans le monde entier.
IPv6 réseau pris en charge
français
English
中文
Deutsch
русский
español
português
العربية
日本語
한국의
Türkçe
